Rationale for Combining a Modified IL-2 and Nivolumab in Melanoma
July 8th 2019Nikhil I. Khushalani, MD, discusses the rationale for combining nivolumab with bempegaldesleukin for the treatment of patients with newly diagnosed, unresectable or metastatic melanoma in a randomized, open-label phase III trial.